Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
Source: SeekingAlpha
2026-03-09 16:07:53 ET
Investment Overview
I have been covering CRISPR Therapeutics AG ( CRSP ), the Zug, Switzerland-based gene therapy developer that leverages the Nobel Prize-winning CRISPR /Cas9 gene editing biotechnology pioneered by Dr. Emmanuelle Charpentier, a scientific co-founder of the company, and others, since I first published a note on the company in May 2021, issuing a Buy recommendation. ...
Read the full article on Seeking Alpha
For further details see:
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
0.03% G/L:
$12.73 Last:
1,289,650 Volume:
$13.02 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
